Guggenheim assumed coverage of Nuvalent (NUVL) with a Buy rating and price target of $122, up from $105.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent initiated with an Outperform at Raymond James
- Nuvalent initiated with an Overweight at Piper Sandler
- Nuvalent Reports Q2 2025 Financials and Pipeline Progress
- Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating
- Nuvalent’s Promising Developments and Strong Financial Position Justify Buy Rating